Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01755767 · ClinicalTrials.gov registry record · Phase 3
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3 study of Hepatocellular Carcinoma, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 3
- Development phase
- 383
- Enrollment target
- 20
- Study locations
NCT01755767 is a Phase 3 study of Hepatocellular Carcinoma that has completed, run by Daiichi Sankyo. The registered enrollment target is 383 participants, above the 255-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (50% higher). The trial reports 20 study locations across 17 states.
The verdict
NCT01755767, a Phase 3 study of Hepatocellular Carcinoma, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 383 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if tivantinib (ARQ 197) is effective in treating patients with MET diagnostic-high hepatocellular carcinoma (liver cancer) who have already been treated once with another therapy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tivantinib
Study Locations (20)
Texas
- - Dallas
- - Galveston
- - Houston
California
- - Los Angeles
- - Orange
Arizona
- - Tucson
District of Columbia
- - Washington D.C.
Florida
- - Gainesville
Illinois
- - Chicago
Kansas
- - Westwood
Louisiana
- - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 383 participants |
| Start Date | 2012-12-27 |
| Est. Completion | 2017-07-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01755767
The ClinicalTrials.gov registry entry for NCT01755767 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 383 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 255-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (50% higher). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01755767 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Texas, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT01755767 about?
NCT01755767 is a clinical study titled "Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy". The purpose of this study is to determine if tivantinib (ARQ 197) is effective in treating patients with MET diagnostic-high hepatocellular carcinoma (liver cancer) who have already been treated once with another therapy.
What is the current status of trial NCT01755767?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 383 participants. The study started on 2012-12-27. Estimated completion is 2017-07-31.
What conditions does trial NCT01755767 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT01755767?
The interventions under investigation include: Placebo (DRUG), Tivantinib (DRUG).
Who is sponsoring clinical trial NCT01755767?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01755767 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
RECRUITING · Phase 3
-
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
RECRUITING · Phase 3
-
Evaluating Novel Therapies in ctDNA Positive GI Cancers
RECRUITING · Phase 3
-
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
ACTIVE NOT RECRUITING · Phase 3
-
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.